IPO PTC Therapeutics (PTCT) is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. Their lead product candidate is ataluren for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. PTC Therapeutics applies proprietary technologies and knowledge of post-transcriptional control processes in drug discovery and development activities. They discovered ataluren by applying their technologies to identify molecules that promote or enhance the suppression of nonsense mutations.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
No comments:
Post a Comment